Purchase this article with an account.
Brandy Hayden, Maria-Elena Jockovich, Timothy G. Murray, Martina T. Kralinger, Monika Voigt, Eleut Hernandez, William Feuer, Jean-Marie Parel; Iontophoretic Delivery of Carboplatin in a Murine Model of Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2006;47(9):3717-3721. doi: 10.1167/iovs.06-0365.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
purpose. To evaluate the efficacy and dose–response of transcorneoscleral Coulomb controlled iontophoresis (CCI) of carboplatin in the treatment of retinal tumors of a murine model of retinoblastoma.
methods. Thirty 6-week-old LHBETATAG mice underwent a total of six, serial iontophoretic treatments administered two times per week using a current density of 2.57 mA/cm2 for 5 minutes. Fourteen animals received carboplatin treatments at concentrations of 1.4, 7.0, 10.0, or 14.0 mg/mL without current. Ten control mice underwent treatment with balanced saline solution.
results. A dose-dependent inhibition of intraocular tumor was observed after repetitive iontophoretic treatment. At carboplatin concentrations of 7 mg/mL, 50% of the treated eyes (4/8) exhibited tumor control. No corneal toxicity was observed in eyes treated at carboplatin concentrations under 10 mg/mL.
conclusions. CCI delivery of carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this murine model of retinoblastoma. CCI is a noninvasive, painless option for the focal delivery of carboplatin. However, further clinical and laboratory research is needed before this method of drug delivery is available for children with retinoblastoma.
This PDF is available to Subscribers Only